Clinical Trials Logo

Clinical Trial Summary

Background:

- Magnetic resonance imaging (MRI) creates high-quality images of the human body without x-rays. It uses a strong magnetic field and radio waves to take pictures. Researchers want to test a scanner that uses a high magnetic field strength.

Objective:

- To study how the body responds to being in a high field 11.7T MRI scanner.

Eligibility:

- Healthy people ages 22 65.

Design:

- Participants will be screened with a medical history and physical exam. They will complete a healthy volunteer questionnaire and an MRI safety screening form. They may have a 3T MRI scan of the brain.

- Participants will have an MRI scan. They will lie on a table that will slide in and out of the MRI cylinder very slowly. They will be asked to lie still.

- Participants will do simple tasks while inside the machine. These can include listening and responding to questions, tapping fingers, or moving a hand.

- While in the scanner, participants will hear loud knocking noises. They will get earmuffs.

- Right when they exit the scanner, participants will get a questionnaire to fill out. This will ask about how they felt inside the scanner.

- During the MRI, participants heart rate, respiratory rate, and skin temperature will be measured. Before and after the scan, these things plus blood pressure will be measured.

- Participants will be tested before and after being in the MRI scanner. They will answer questions, take pen-and-paper or computer tests, and do simple actions. Their sense of smell may be tested.


Clinical Trial Description

Objective

The goals of this pilot study are to establish a normative database of vital signs, cognitive function and unusual subjective sensations in a 0T scanner. This data will be used as a reference for a future study of the effects of exposure to a 11.7T static magnetic field.

Study Population

26 healthy volunteers, aged 22-65.

Accrual ceiling =50

Accrual Target =26

Drop outs will be replaced

Design

The study consists of one outpatient screening session and one experimental session. Informed consent and a history and neurological examination will be carried out at the screening visit. Vital signs (pulse oximeter, heart rate, respiratory rate and skin temperature) will be measured immediately before and after the experimental scan session, and pulse oximeter, heart rate and respiration will be monitored when the subject is in the scanner. Subjects will remain in the scanner for approximately 1 hour. During the experimental session, while the subject is in the scanner, they will be asked to carry out a brief test of attention at 10-15 minute intervals, up to 3 times during the session. At the end of the experimental session, subjects will fill out the MRI exit questionnaire to rate subjective sensations such as nausea, vertigo, and lightheadedness, on a Likert scale and complete a computerized neuro-cognitive test battery.

Outcome Measures

The objective of the study is to obtain a normative dataset of neuropsychological test measures, physiological parameters, and subjective experiences measures in subjects undergoing 0T exposure. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02339883
Study type Observational
Source National Institutes of Health Clinical Center (CC)
Contact
Status Withdrawn
Phase
Start date December 23, 2014
Completion date September 27, 2019

See also
  Status Clinical Trial Phase
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1